Apollo Endosurgery Inc
F:HQ8F
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
Apollo Endosurgery Inc
Cash Equivalents
Apollo Endosurgery Inc
Cash Equivalents Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Cash Equivalents | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
A
|
Apollo Endosurgery Inc
F:HQ8F
|
Cash Equivalents
$57m
|
CAGR 3-Years
24%
|
CAGR 5-Years
13%
|
CAGR 10-Years
9%
|
|
|
Boston Scientific Corp
NYSE:BSX
|
Cash Equivalents
$2B
|
CAGR 3-Years
51%
|
CAGR 5-Years
-1%
|
CAGR 10-Years
19%
|
|
|
Edwards Lifesciences Corp
NYSE:EW
|
Cash Equivalents
$2.9B
|
CAGR 3-Years
50%
|
CAGR 5-Years
20%
|
CAGR 10-Years
19%
|
|
|
Stryker Corp
NYSE:SYK
|
Cash Equivalents
$4B
|
CAGR 3-Years
30%
|
CAGR 5-Years
6%
|
CAGR 10-Years
2%
|
|
|
Abbott Laboratories
NYSE:ABT
|
Cash Equivalents
$8.5B
|
CAGR 3-Years
-2%
|
CAGR 5-Years
1%
|
CAGR 10-Years
10%
|
|
|
Intuitive Surgical Inc
NASDAQ:ISRG
|
Cash Equivalents
$2.9B
|
CAGR 3-Years
38%
|
CAGR 5-Years
24%
|
CAGR 10-Years
15%
|
|
Apollo Endosurgery Inc
Glance View
Apollo Endosurgery, Inc. is a medical technology company, which focuses on the design, development, and commercialization of medical devices to advance gastrointestinal therapeutic endoscopy. The company is headquartered in West Lake Hills, Texas and currently employs 107 full-time employees. The company went IPO on 2005-04-21. The firm develops and distributes devices that are used by surgeons and gastroenterologists for various procedures related to gastrointestinal conditions including closure of gastrointestinal defects, managing gastrointestinal complications and the treatment of obesity. The firm's products include the OverStitch Endoscopic Suturing System, which enables advanced endoscopic procedures from within the Gastrointestinal tract, or endolumenally, by allowing physicians to suture, especially full-thickness, and secure the approximation of tissue. The X-Tack Endoscopic HeliX Tacking System is a suture-based device designed specifically for closing and healing defects in the lower gastrointestinal tract. The Orbera Intragastric Balloon System is a non-surgical alternative for interventional weight loss.
See Also
What is Apollo Endosurgery Inc's Cash Equivalents?
Cash Equivalents
57m
USD
Based on the financial report for Dec 31, 2022, Apollo Endosurgery Inc's Cash Equivalents amounts to 57m USD.
What is Apollo Endosurgery Inc's Cash Equivalents growth rate?
Cash Equivalents CAGR 10Y
9%
Over the last year, the Cash Equivalents growth was -37%. The average annual Cash Equivalents growth rates for Apollo Endosurgery Inc have been 24% over the past three years , 13% over the past five years , and 9% over the past ten years .
